80
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

      review-article
      , MD a , , , MD a , b , , , MD, MS a , b , c , , PharmD a , , MD a ,   , MD, MStat d , e , , MD f , , PharmD a , , MD, PhD g , , MD a , , MD a , , MD h , , MD, SM a , b , , MD b , i , , MD SM c , j , k , , MD a , b ,
      Journal of the American College of Cardiology
      by the American College of Cardiology Foundation. Published by Elsevier.
      cardiovascular therapy, coronavirus, health system, ACE2, angiotensin-converting enzyme 2, ARB, angiotensin receptor blocker, ARDS, acute respiratory distress syndrome, CI, confidence interval, COVID-19, coronavirus disease 2019, CV, cardiovascular, CVD, cardiovascular disease, ECMO, extracorporeal membrane oxygenation, ICU, intensive care unit, MI, myocardial infarction, PPE, personal protective equipment, RNA, ribonucleic acid, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and pre-existing cardiovascular disease have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become hosts or vectors of virus transmission. We hereby review the peer-reviewed and pre-print reports pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.

          Central Illustration

          Highlights

          • Patients with pre-existing CVD appear to have worse outcomes with COVID-19.

          • CV complications include biomarker elevations, myocarditis, heart failure, and venous thromboembolism, which may be exacerbated by delays in care.

          • Therapies under investigation for COVID-19 may have significant drug-drug interactions with CV medications.

          • Health care workers and health systems should take measures to ensure safety while providing high-quality care for COVID-19 patients.

          Related collections

          Most cited references62

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

          Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical Characteristics of Coronavirus Disease 2019 in China

            Abstract Background Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of the affected patients. Methods We extracted data regarding 1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China through January 29, 2020. The primary composite end point was admission to an intensive care unit (ICU), the use of mechanical ventilation, or death. Results The median age of the patients was 47 years; 41.9% of the patients were female. The primary composite end point occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Only 1.9% of the patients had a history of direct contact with wildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of Wuhan, including 31.3% who had visited the city. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). Diarrhea was uncommon (3.8%). The median incubation period was 4 days (interquartile range, 2 to 7). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with nonsevere disease and in 5 of 173 patients (2.9%) with severe disease. Lymphocytopenia was present in 83.2% of the patients on admission. Conclusions During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness. Patients often presented without fever, and many did not have abnormal radiologic findings. (Funded by the National Health Commission of China and others.)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              A pneumonia outbreak associated with a new coronavirus of probable bat origin

              Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats 1–4 . Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans 5–7 . Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.
                Bookmark

                Author and article information

                Contributors
                @sahilparikhmd
                Journal
                J Am Coll Cardiol
                J. Am. Coll. Cardiol
                Journal of the American College of Cardiology
                by the American College of Cardiology Foundation. Published by Elsevier.
                0735-1097
                1558-3597
                19 March 2020
                12 May 2020
                19 March 2020
                : 75
                : 18
                : 2352-2371
                Affiliations
                [a ]New York–Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York
                [b ]Clinical Trials Center, Cardiovascular Research Foundation, New York, New York
                [c ]Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut
                [d ]Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
                [e ]Mediterranea Cardiocentro, Napoli, Italy
                [f ]Massachusetts General Hospital, Boston, Massachusetts
                [g ]Case Western Reserve School of Medicine, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio
                [h ]Vanderbilt University Medical Center, Nashville, Tennessee
                [i ]Icahn School of Medicine at Mount Sinai, New York, New York
                [j ]Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
                [k ]Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut
                Author notes
                [] Address for correspondence: Dr. Sahil A. Parikh, Columbia University Irving Medical Center, New York–Presbyterian Hospital, 161 Fort Washington Avenue, 6th Floor, New York, New York 10032. sap2196@ 123456cumc.columbia.edu @sahilparikhmd
                [∗]

                Drs. Driggin and Madhavan contributed equally to this work.

                Article
                S0735-1097(20)34637-4
                10.1016/j.jacc.2020.03.031
                7198856
                32201335
                da9636a8-33a7-4c13-8686-b511633d067e
                © 2020 by the American College of Cardiology Foundation. Published by Elsevier.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 17 March 2020
                : 17 March 2020
                Categories
                Article

                Cardiovascular Medicine
                cardiovascular therapy,coronavirus,health system,ace2, angiotensin-converting enzyme 2,arb, angiotensin receptor blocker,ards, acute respiratory distress syndrome,ci, confidence interval,covid-19, coronavirus disease 2019,cv, cardiovascular,cvd, cardiovascular disease,ecmo, extracorporeal membrane oxygenation,icu, intensive care unit,mi, myocardial infarction,ppe, personal protective equipment,rna, ribonucleic acid,sars-cov-2, severe acute respiratory syndrome coronavirus 2

                Comments

                Comment on this article